This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Wall Street Losing Patience With Amarin

BOSTON ( TheStreet) -- I warned last month about Wall Street being hostile to Amarin (AMRN) launching the prescription fish-oil pill Vascepa on its own.

Wedbush analyst Akiva Felt today:

We are downgrading shares of Amarin from Outperfrom to Neutral as we view the risk/reward to be less favorable now that October is underway. In sum, the downgrade is based on our view that:

1) The absence of a deal by now suggests that any potential acquisition premium is unlikey to meet the Street's lofty expectations.

2) A potential near-term announcement that Amarin has begun hiring a sales force for Vascepa represents a concrete negative catalyst, which management previously guided would occur in October (in the absence of a deal.)

3) Given the continued vacuum of information surrounding the status of Amarin's negotiations, we believe shares will trend lower as time passes in October as investors grow incrementally more fearful that a deal may fail to materialize.

Well said, Akiva. He's come around to my argument:

"If Amarin fails to gain NCE [New Chemical Entity] status, the odds increase that the company is forced to launch Vascepa on its own, without a major pharmaceutical partner or a buyer of the entire company. Wall Street investors aren't going to like a solo Vascepa launch at all."

Felt, again, from today's downgrade:

"In sum, if big pharma (collectively) does indeed view Amarin to be a high-priority acquisition target as we previously hypothesized, we believe a bidder willing to forego definitive resolution on the remaining uncertainties like NCE would step forward and offer a price inline with Street expectations. However, we believe such a transaction would most likely have occurred by now, and by mid-October at the latest."

As the days click by, an Amarin takeout, if one were to occur, is more likely to be priced in the $15-20 per share range and not the $25-30 per share range that Amarin bulls expect, Felt adds.

Amarin shares are down 5% to $11.76 in Wednesday trading.

-- Reported by Adam Feuerstein in Boston.

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AMRN $1.88 -1.10%
AAPL $94.88 -0.32%
FB $117.69 0.22%
GOOG $694.35 0.29%
TSLA $231.85 -0.20%


Chart of I:DJI
DOW 17,724.51 -26.40 -0.15%
S&P 500 2,056.47 -6.90 -0.33%
NASDAQ 4,749.7220 -13.5020 -0.28%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs